Cytek Biosciences, Inc. (CTKB)
NASDAQ: CTKB · Real-Time Price · USD
3.950
+0.050 (1.28%)
Oct 9, 2025, 4:00 PM EDT - Market closed
Cytek Biosciences Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | -6.4 | -6.02 | -12.15 | 2.48 | 3.03 | 19.41 |
Depreciation & Amortization | 11.42 | 10.49 | 9.23 | 5.66 | 1.24 | 0.6 |
Stock-Based Compensation | 27.48 | 26.85 | 22.05 | 16.6 | 6.59 | 0.61 |
Other Adjustments | -12.34 | -13.65 | -3.34 | 2.96 | 2.42 | 2.07 |
Change in Receivables | -8.48 | -5.43 | -7.33 | -19.74 | -12.37 | 0.33 |
Changes in Inventories | 0.48 | 14.76 | 4.29 | -17.65 | -7.07 | -5.7 |
Changes in Accounts Payable | 3.66 | 2.58 | -1.78 | 1.86 | -0.26 | -0.06 |
Changes in Accrued Expenses | 9.24 | -0.82 | 0.73 | 7.47 | 10.98 | 3.27 |
Changes in Unearned Revenue | 4.74 | 3.74 | 6.52 | 9.41 | 10.01 | 2.38 |
Changes in Other Operating Activities | -9.63 | -7.12 | -12.93 | -21.27 | -9.95 | -7.76 |
Operating Cash Flow | 15.2 | 25.38 | 5.28 | -12.23 | 4.63 | 15.16 |
Operating Cash Flow Growth | -1.51% | 380.57% | - | - | -69.45% | - |
Capital Expenditures | -4.33 | -3.53 | -4.65 | -9.75 | -4.36 | -1.55 |
Sale of Property, Plant & Equipment | 0.27 | 0.29 | - | - | - | - |
Purchases of Intangible Assets | -0.08 | -0.2 | -0.18 | -0.12 | - | - |
Purchases of Investments | -301.5 | -274.06 | -175.94 | -46.04 | - | - |
Proceeds from Sale of Investments | 219.91 | 195 | 132 | - | - | - |
Payments for Business Acquisitions | - | -0.47 | -44.9 | - | -17 | - |
Other Investing Activities | - | - | -0.24 | - | 0.37 | - |
Investing Cash Flow | -86.2 | -82.97 | -93.89 | -55.91 | -20.99 | -1.55 |
Short-Term Debt Issued | 4.87 | 4.18 | - | - | - | - |
Net Short-Term Debt Issued (Repaid) | 4.87 | 4.18 | - | - | - | - |
Long-Term Debt Issued | - | - | - | 2.98 | - | 4.08 |
Long-Term Debt Repaid | -1.94 | -0.56 | -0.57 | -0.05 | -2.77 | -1.31 |
Net Long-Term Debt Issued (Repaid) | -1.94 | -0.56 | -0.57 | 2.93 | -2.77 | 2.77 |
Issuance of Common Stock | 0.39 | 2.72 | 3.32 | 2.79 | 216.33 | 0.17 |
Repurchase of Common Stock | -34.08 | -21.61 | -44.15 | - | - | - |
Net Common Stock Issued (Repurchased) | -33.69 | -18.89 | -40.83 | 2.79 | 216.33 | 0.17 |
Issuance of Preferred Stock | - | - | - | - | - | 119.67 |
Net Preferred Stock Issued (Repurchased) | - | - | - | - | - | 119.67 |
Other Financing Activities | -0.51 | -0.55 | -0.42 | -0.21 | - | - |
Financing Cash Flow | -29.87 | -15.82 | -41.81 | 5.51 | 213.56 | 122.61 |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | -1.57 | 4.53 | -1.45 | -2.49 | 1.3 | -0.59 |
Net Cash Flow | -102.45 | -68.89 | -131.87 | -65.12 | 198.5 | 135.63 |
Beginning Cash & Cash Equivalents | 177.92 | 167.63 | 299.5 | 364.62 | 166.12 | 30.49 |
Ending Cash & Cash Equivalents | 75.47 | 98.75 | 167.63 | 299.5 | 364.62 | 166.12 |
Free Cash Flow | 10.87 | 21.85 | 0.63 | -21.98 | 0.27 | 13.61 |
Free Cash Flow Growth | -50.26% | 3352.45% | - | - | -98.05% | - |
FCF Margin | 5.54% | 10.90% | 0.33% | -13.40% | 0.21% | 14.66% |
Free Cash Flow Per Share | 0.08 | 0.17 | 0.00 | -0.16 | 0.00 | 0.42 |
Levered Free Cash Flow | 12.1 | 17.71 | -11.31 | -18.76 | 3.88 | -2.83 |
Unlevered Free Cash Flow | -7.17 | -1.57 | -20.13 | -27.83 | 5.27 | 9.56 |
Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.